SAM
PCRX icon

SignalPoint Asset Management’s Pacira BioSciences PCRX Stock Holding History

SignalPoint Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,321
Closed -$279K – 221
2019
Q3 		$279K Sell
7,321
-3,119
-30% -$124K 0.12% 177
2019
Q2 		$454K Buy
+10,440
New +$443K 0.22% 118

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SignalPoint Asset Management's PCRX Position: Q4 2019 in Review

SignalPoint Asset Management sold out of Pacira BioSciences (PCRX) in Q4 2019, closing a stake of 7,321 shares — an estimated $279K sold.

SignalPoint Asset Management first reported a position in PCRX in Q2 2019 and held it in 2 quarters. The position peaked at $454K in Q2 2019. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

  • SignalPoint Asset Management reported no remaining Pacira BioSciences position as of Q4 2019 after selling out during the quarter.
  • SignalPoint Asset Management sold 7,321 Pacira BioSciences shares in Q4 2019, an estimated $279K.
  • SignalPoint Asset Management first reported a position in Pacira BioSciences in Q2 2019 and held it in 2 quarters.
  • SignalPoint Asset Management's Pacira BioSciences position peaked at $454K in Q2 2019.
  • 231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on SignalPoint Asset Management's 13F filing for Q4 2019, filed 30 Jan 2020.